This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The artificial sweetener sucralose (marketed as Splenda) is widely used and found in products like diet soda and chewing gum. According to a new study, it’s also capable of damaging the DNA material inside our cells.
BRCA1 (BReast CAncer Gene 1), a key gene that becomes faulty in some instances, leading to breast and ovarian cancer, plays an important role in the body's DNA repair mechanisms. BRCA1, once mutated, can cause cancer to develop.
For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition. These advanced therapeutics harness the power of molecular biology to improve human health.
GE Research selected DNA Script to join a collaboration working on a rapid response, mobile platform to develop on-demand production of nucleic acid-based vaccines and therapies related to biological threats.
firm best known for its niche approach to DNA sequencing, on Tuesday announced plans to launch a new product that will put the company in direct competition with genomics juggernaut Illumina. The new DNA sequencer, dubbed Onso, reads the genome in small pieces and uses software to stitch that information together.
VGXI, Inc, a provider of plasmid DNA manufacturing and development services, says multiple construction milestones have been reached for its new headquarters and manufacturing facility in Texas.
The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.
SAN DIEGO — After a steep drop in its stock price and with mounting competition from rivals, genomics giant Illumina on Thursday launched a new line of high-powered DNA sequencers, ratcheting up the race to read genetic information accurately and cheaply. Continue to STAT+ to read the full story…
The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Polyplus, based in Strasbourg, France, produces key components in the production of viral vectors used in cell and gene therapies.
Sediments in which archaeological finds are embedded have long been regarded by most archaeologists as unimportant by-products of excavations. However, in recent years it has been shown that sediments can contain ancient biomolecules, including DNA.
These small, circular DNA molecules are used by scientists to introduce new genes into a target organism. Well known for their applications in the production of therapeutic proteins like insulin, plasmids are broadly used in the large-scale production of many bioproducts. Plasmids have extensive use in basic and applied biology.
Developing neoantigen products needed for the therapy has faced difficulties including lead time to get GMP DNA and complicated supply chains. With a five-day manufacturing process, the enzymatic production approach of Touchlight will back Odimma in developing its programme. .
The gene-editing technology allows for precise, directed changes to genomic DNA. It edits genes by precisely cutting DNA, then allowing natural DNA repair processes to take over. The system comprises the Cas9 enzyme and a guide RNA.
A team of geneticists and archaeologists from Ireland, France, Iran, Germany, and Austria has sequenced the DNA from a 1,600-year-old sheep mummy from an ancient Iranian salt mine, Chehr?b?d. Credit: Deutsches Bergbau-Museum Bochum and Zanjan Cultural Heritage Centre, Archaeological Museum of Zanjan.
Integrated DNA Technologies (IDT) is doubling down on its commitment to innovation with the launch of a new 25,000-square-foot synthetic biology facility in Coralville, Iowa.
coli enzyme synthesizing ribosomal RNA that shift it between turbo- and slow-modes depending on the bacteria’s growth rate Credit: Murakami Laboratory, Penn State The enzyme that makes RNA from a DNA template is altered to slow the production of ribosomal RNA (rRNA), the […].
GenScript ProBio has announced a strategic collaboration with RVAC Medicines to manufacture GMP-grade plasmid DNA (pDNA) for the latter’s RVM-V001, an mRNA Covid-19 vaccine candidate. Under the agreement, GenScript ProBio will offer GMP plasmid manufacturing service for the RVM-V001 programme.
Slick productions to maximise digital opportunities and algorithm-powered insights play a strong role in linking industry campaigns to the healthcare coal face but deeper connections can be mined by making coaching part of an organisation’s DNA. Coaching has to be part of the DNA,” he adds. “It A critical mind-shift is needed.
The researchers used DNA barcoding to investigate the occurrence of shark in different pet food products purchased in Singapore, which revealed a considerable prevalence of ingredient mislabeling. They suggested implementing global […].
In an email to Pharmaceutical Technology , an NHSBT spokesperson said the centre will “support early phase clinical trials and preclinical work, providing a route to eventual commercial scale production”. The NHSBT representative explained that a lack of manufacturing spaces led to delays in production slots for many gene therapy developers.
Genetic engineering has the potential to transform how we raise animals for meat and other products, making food safer, improving animal health and welfare, and shrinking animal agriculture’s environmental footprint. Pigs that are less likely to induce allergic reactions in humans.
Polyplus, a provider of transfection reagents, has acquired e-Zyvec, a France-based provider of DNA design and production services for tailor-made DNA vectors to expand expertise in plasmid DNA vector engineering.
Together, the addition of pDNA technology and production capabilities. SOMERSET, N.J. SOMERSET, N.J. Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility.
DNA data storage involves encoding and decoding binary data to and from synthesized strands of DNA. DNA data storage is an innovative technology that works by encoding large digital data sequences of binary form (0s and 1s) into DNA sequences (Adenine (A), Guanine (G), Cytosine (C) and Thymine (T)). DNA Storage.
Recent pre-mass production trials tests conducted to ensure that the devices meet performance and manufacturing quality standards before full-scale production demonstrated that the A+Pre chip recovered 94% of tumor cells, while the AC-1000 achieved a 79.5% recovery rate, surpassing their performance targets.
DNA Script Joins Wellcome Leap R3 Program to Advance RNA Products and Therapies DNA Script Joins Wellcome Leap R3 Program to Advance RNA Products and Therapies Multi-year, multi-million dollar collaboration will develop new tools to rapidly accelerate the development of … Continue reading →
DNA Sequencing Products Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 – ResearchAndMarkets.com DNA Sequencing Products Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “DNA Sequencing Products (..)
Ribbon Biolabs Raises EUR 18 Million Series A Financing Enabling Commercial Scale Production Facilities and US Expansion for DNA Synthesis Technology Ribbon Biolabs Raises EUR 18 Million Series A Financing Enabling Commercial Scale Production Facilities and US Expansion for DNA … Continue reading →
CHF 637,87Angebotsende: Mittwoch Sep-16-2020 4:36:52 CESTSofort-Kaufen für nur: CHF 637,87Sofort-Kaufen | Zur Liste der beobachteten Artikel hinzufügen Biotech365 : Qiagen QIAxcel for DNA Fragment & RNA Analysis BioMarketplace You want to propose your products or a Biotech Company, a Biotech … Continue reading →
–(BUSINESS WIRE)–$APDN #COVID19–Applied DNA Sciences, Inc. NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product … Continue reading →
Wheeler is missing the DNA needed to recycle a waste product called lipofuscin that his cells naturally produce. Juvenile Batten disease — he has the type known as CLN3 — is stealing his childhood. And then this rare disease will steal my child.
The multi-year collaboration will focus on discovering precision genetic medicines by developing a new platform for complete gene insertion by delivering a single vector of gene editing and DNA cargo. The new solution will enable complete gene insertion by delivering the gene-editing tool and DNA as mixed cargo to desired targets in one LNP.
Biopharma companies are under pressure to do more with less in the production of monoclonal antibody (mAb) therapies. However, these processes can damage cells, resulting in more impurities in the downstream process to remove and decreasing the product quality. The first is to increase the specific productivity of the cells.
The novel silicon chip is a key component of Evonetix’s desktop DNA platform which, once fully developed, will facilitate and enable the rapidly growing field of synthetic biology.
Gene therapy uses DNA to manipulate cells and correct defective genes, whereas cell therapy is the infusion or transplantation of cells into a patient. New doors were opened in the 2000s with the development of genome editing, such as CRISPR-Cas9, which introduces molecular tools to change existing DNA.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content